Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

About this update from Unicycive Therapeutics, Inc.

LOS ALTOS, Calif. , Sept. 05, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics , Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta , M.D., Chief Executive Officer will present a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024 at 10:30 a.m. ET in New York, NY . A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations . An archive of the webcast will be available for three months. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn , X , and YouTube . Investor Contact: [email protected] (650) 543-5470 SOURCE: Unicycive Therapeutics, Inc. Source: Unicycive Therapeutics, Inc.

View stock analysis, news, and events for Unicycive Therapeutics, Inc.